垂体腺瘤内镜经鼻术后按风险调整停用口服抗凝药后的术后血肿发生率
单中心回顾性病例系列分析2008年12月至2022年7月接受内镜经鼻蝶手术的垂体腺瘤患者,其中20例术前口服抗凝药。按个体风险评估和近期一般推荐暂停抗凝后,口服抗凝药组术后出血未见较无抗凝药组显著增加。
要点
- 305例垂体腺瘤患者中20例术前口服抗凝药,包括非瓣膜性房颤10例和静脉血栓栓塞事件8例。
- 直接口服抗凝药术前暂停1-3天(43.6±23.6小时),苯丙香豆素暂停234±123.55小时。
- 口服抗凝药组术后出血未见较无抗凝药组显著增加。
核心结论
- 按个体风险评估和近期一般推荐暂停口服抗凝药后,内镜经鼻蝶手术治疗垂体腺瘤患者术后血肿风险未见增加。
研究设计与样本
- 单中心回顾性病例系列,连续纳入2008年12月至2022年7月接受内镜经鼻蝶手术的垂体腺瘤患者,共305例,其中20例术前口服抗凝药。
主要发现
- 305例患者中20例术前口服抗凝药,适应证包括非瓣膜性房颤10例和既往静脉血栓栓塞事件8例,2例有重叠适应证。
- 12例直接口服抗凝药患者术前暂停1-3天(43.6±23.6小时),苯丙香豆素术前暂停234±123.55小时(最短6小时,最长22天)。
- 年龄、性别、肿瘤生长方向、肿瘤体积和最大直径等基线特征组间无显著差异。
- 口服抗凝药组术后出血较无抗凝药组未见显著增加;1例术前48小时暂停阿哌沙班的患者发生术后鼻出血。
- 无口服抗凝药患者中1例发生颅内出血、7例发生鼻出血。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study describes the management of patients on oral anticoagulation (OAC) undergoing endoscopic endonasal transsphenoidal surgery (EETS) and analyzes the risk of postoperative hematoma and epistaxis following treatment of pituitary adenoma (PA). METHODS: Patients with OAC prior to EETS for PA were analyzed in a single center retrospective case series of consecutive patients with PA, who were treated between December 2008 and July 2022. Patient data (age, sex, clinical, endocrinology, tumor histology) were entered into a SPSS® database. The rate of postoperative hemorrhage (intracranial and epistaxis) and other perioperative complications were assessed. RESULTS: Of 305 patients, 20 patients were on OAC prior to EETS for PA. Indications included non-valvular atrial fibrillation (AF) in 10 patients and previous venous thromboembolic event (VTE) in 8 patients, in 2 patients had overlapping indications. Twelve patients on direct oral anticoagulants (DOAC) paused medication 1-3 days (43.6 ± 23.6 h) before surgery, while phenprocoumon was paused 234 ± 123.55 h (min 6, max 22 days) before surgery. Baseline characteristics such as age, sex, tumor growth direction, tumor volume, and largest diameter showed no significant differences. No significant increase in postoperative hemorrhage was observed in patients with OAC compared to those without. One patient on apixaban paused 48 h before surgery experienced postoperative epistaxis. Among patients without OAC, one experienced intracranial hemorrhage and seven experienced epistaxis. CONCLUSION: Patients with OAC prior to EETS for PA have no increased risk for postoperative hematoma when OAC is paused based on individual risk assessment and recent general recommendations.
引用
- Loeschner D, Enciu A, Wagle PR, et al. The rate of postoperative hematoma following risk-adapted cessation of oral anticoagulation in patients undergoing endoscopic endonasal surgery for pituitary adenomas. Acta Neurochir (Wien). 2024. PMID: 39643762. doi:10.1007/s00701-024-06387-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。